PD-L1 Biomarker for Immunotherapy
In March 2019, the FDA approved atezolizumab (Tecentriq®), the first PD-1/PD-L1 immune checkpoint inhibitor for metastatic triple-negative breast cancer, based on...
Read MoreDepression & Metastatic Breast Cancer
Depression is common after a metastatic breast cancer diagnosis, whether caused by treatment or emotional stress. Getting support can improve emotional and...
Read MoreLBBC’s Conference on Metastatic Breast Cancer
In June, Living Beyond Breast Cancer (LBBC) held its Annual Conference on Metastatic Breast Cancer. Due to COVID-19 the event was held virtually. You can watch...
Read MoreMetastatic Breast Cancer at a Young Age
Metastatic breast cancer can happen to anyone, including young people. Most research considers a person “young” if they’ve been diagnosed with...
Read MoreHow Participants are Divided into Treatment Groups in Clinical Trials
Randomization is part of clinical trial design that helps researchers prevent accidental bias in the trial results meaning that no outside factors shifted the...
Read MoreSexual Side Effects of MBC Treatment
Metastatic breast cancer and its treatments can cause sexual side effects and impact your sex life. Fatigue and emotional stress from living with cancer can lower...
Read MoreWhat is ER-Low Breast Cancer?
Did you know that some breast cancers can be defined as estrogen receptor low (ER-low) breast cancer? When you’re first diagnosed, a pathologist runs a...
Read MoreClinical Trials Are Not Only a Last Resort
It’s a myth that you should only join a metastatic breast cancer clinical trial when you have no other treatment options here’s why. In general, you...
Read MoreSpotlight on Metastatic Breast Cancer in Older People
Geriatric oncology is a specialty that focuses on treating and researching cancer in older people. As we age, our bodies are more likely to develop many different...
Read MoreSEARCH OUR SITE
for past articles or specific information.